Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...
Novo Nordisk’s Ozempic and Lilly’s Mounjaro treat Type 2 diabetes, while Wegovy and Zepbound are anti-obesity medications. The FDA has long warned that compounded medications, which it doesn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback